Subscribe to our Newsletter
Karolinska Institutet is a renowned public institution at the cutting edge of medical research. Karolinska Institutet (KI) is one of the world’s leading medical universities, located in Stockholm, Sweden.
Founded in 1810, KI is renowned for its significant contributions to medical research and education. It is closely associated with the Nobel Assembly. KI is recognized for its cutting-edge research in various fields, including regenerative medicine, neuroscience, immunology, and cancer.
The Department of Laboratory Medicine – Biomolecular Medicine and Advanced Therapies is committed to studying efficient means of delivering promising therapeutics to the right organ with the right dose, offering groundbreaking solutions to make promising therapeutic approaches available to patients.
The current characterization of extracellular vesicles (EVs) and lipid nanoparticles (LNPs) relies on destructive methods, such as dynamic light scattering and nanoparticle tracking analysis, which do not analyze particles in their native form. These approaches face challenges like variability in formulations, complex cargo-loading assessments, and batch consistency evaluation.
To address these issues, innovative solutions are sought to enable non-destructive, accurate characterization of biophysical and chemical properties, fast data generation, and integration with existing infrastructure. Such techniques must support regulatory compliance and quality control in therapeutic nanoformulation production.
iLoF’s cutting-edge solution provides a multi-parameter analytical platform for the characterization of biophysical and chemical properties of complex nanoformulations, like extracellular vesicles (EVs) and lipid nanoparticles (LNP). By leveraging multi-dimensional optical data, our platform delivers next-generation profiling of nanoparticles in liquid specimens, with key benefits including:
• Label-free, non-destructive quantification of drug load
• Comprehensive multiparameter data to simplify and speed up the analysis process.
• Compatibility with diverse nanoformulations and complex backgrounds.
iLoF maximizes user experience by simplifying sample processing and providing automatic sample handling, remote monitoring, and expedited data analysis. By equipping drug developers with actionable insights, this innovative tool is designed to enable real-time, atline nanoparticle analytics with unparalleled accuracy and efficiency, streamlining the development and production of advanced nanotherapeutics.
The proposed solution aligns with the Challenger’s needs for developing advanced therapeutics, namely:
Precise characterization: accurately measures the physical and chemical properties of EVs and LNPs, including RNA cargo composition and distribution.
Non-destructive analysis: The characterization process is non-destructive, preserving the integrity and therapeutic potential of nanoparticles.
Rapid and actionable data: generates, comprehensive, and reliable data, capturing critical safety, efficacy, and regulatory parameters in a single, quick measurement.
User-centric design: ease of use and data interpretation.
This project has received funding from the European Union’s Horizon Europe research and innovation programme under the Grant Agreement 101071212.
Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Innovation Council and SMEs Executive Agency (EISMEA). Neither the European Union nor the granting authority can be held responsible for them.
